On 3/30/2017, Shares of Axcelis Technologies, Inc. (NASDAQ:ACLS) closed at $18.05 in last trading day. After noting the initial trading entry at $16.75, it reached to a day’s high of $18.15 and moved to a day’s low of $16.73. The recent daily volume was 541.83 thousand as contrast to it’s an average volume of 194.09 thousand.
The last close of the Axcelis Technologies, Inc. stock reflects that it traded up +13.97% from its 50-day moving average of $15.84. The stock traded above +25.08% to its 200-day MA of $14.43. Furthermore, it moved lower -0.55% from its 52-week high of $18.15 and +102.35% up from $8.92, which is 52-week low of the stock.
Axcelis Technologies, Inc.’s (ACLS) moved with shift of 14.60% in the past week. Over the last three months, the shares of the company have changed 28.01% and performed 37.16% over the last six months. The stock currently has Monthly Volatility of 3.53% and Weekly Volatility of 4.57%.
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific. The company offers a line of high energy, high current, and medium current implanters for various application requirements. It also provides dry strip equipment, curing systems, and thermal processing systems, as well as services and supports its dry strip installed base. In addition, the company offers aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. It sells its equipment and services to semiconductor chip manufacturers through its direct sales force. The company was founded in 1995 and is headquartered in Beverly, Massachusetts.
Sangamo BioSciences, Inc. (NASDAQ:SGMO) finalized the last transaction at value of $4.70, with a daily change of +1.08% or +0.05 points. The company maintained volume of 518.2 thousand shares. In past trading day, the stock hit the maximum price of $4.80 and touched to minimum value of $4.50. It has a market cap of $ 333.11M.
As of last trade close, the stock is trading downside -38.16% from its one year high of $7.60 and moved +77.36% upward from $2.65, which is one year low of the stock.
The stock traded above +11.49% from its 50-day moving average of $4.22. Furthermore, the stock moved up +20.13% to its 200-day MA of $ 3.91.
During the last month, Sangamo Therapeutics, Inc.’s (SGMO) has changed 0.00% and performed -3.89% over the last 6 months. The mean rating score for this stock is at 2.00. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 6.33% in recent month and observed Weekly Volatility of 7.80%.
March 29, 2017 Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, announced the presentation of new human in vitro and animal model data demonstrating significant reduction of tau mRNA and tau protein expression using the Company’s zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation technology. These results are the first evidence of a tau lowering agent demonstrating efficacy on neuritic dystrophy in an amyloid mouse model of Alzheimer’s disease. The data were presented by Sangamo’s collaborators from Massachusetts General Hospital Alzheimer’s Disease Research Center and Harvard Medical School at the 13th International Conference on Alzheimer’s & Parkinson’s Diseases. The meeting is being held in Vienna, Austria from March 29th to April 2nd.